BR0314872A - Ligandos do receptor canabinóide e usos dos mesmos - Google Patents

Ligandos do receptor canabinóide e usos dos mesmos

Info

Publication number
BR0314872A
BR0314872A BR0314872-6A BR0314872A BR0314872A BR 0314872 A BR0314872 A BR 0314872A BR 0314872 A BR0314872 A BR 0314872A BR 0314872 A BR0314872 A BR 0314872A
Authority
BR
Brazil
Prior art keywords
cannabinoid receptor
receptor ligands
cannabinide
animals
act
Prior art date
Application number
BR0314872-6A
Other languages
English (en)
Inventor
Robert Lee Dow
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of BR0314872A publication Critical patent/BR0314872A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"LIGANDOS DO RECEPTOR CANABINóIDE E USOS DOS MESMOS". A presente invenção refere-se a compostos de fórmula (1) que atuam como ligandos do receptor canabinóide e as suas utilizações no tratamento de doenças ligadas à modulação dos receptores canabinóides em animais.
BR0314872-6A 2002-10-18 2003-10-06 Ligandos do receptor canabinóide e usos dos mesmos BR0314872A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41962102P 2002-10-18 2002-10-18
PCT/IB2003/004411 WO2004035566A1 (en) 2002-10-18 2003-10-06 Cannabinoid receptor ligands and uses thereof

Publications (1)

Publication Number Publication Date
BR0314872A true BR0314872A (pt) 2005-08-02

Family

ID=32108116

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0314872-6A BR0314872A (pt) 2002-10-18 2003-10-06 Ligandos do receptor canabinóide e usos dos mesmos

Country Status (8)

Country Link
US (1) US20040077650A1 (pt)
EP (1) EP1556373A1 (pt)
JP (1) JP2006506366A (pt)
AU (1) AU2003267728A1 (pt)
BR (1) BR0314872A (pt)
CA (1) CA2502511A1 (pt)
MX (1) MXPA05004115A (pt)
WO (1) WO2004035566A1 (pt)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004029204A2 (en) 2002-09-27 2004-04-08 Merck & Co., Inc. Substituted pyrimidines
US7129239B2 (en) 2002-10-28 2006-10-31 Pfizer Inc. Purine compounds and uses thereof
US7247628B2 (en) * 2002-12-12 2007-07-24 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
US7329658B2 (en) * 2003-02-06 2008-02-12 Pfizer Inc Cannabinoid receptor ligands and uses thereof
US7176210B2 (en) * 2003-02-10 2007-02-13 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
US7145012B2 (en) * 2003-04-23 2006-12-05 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
US7268133B2 (en) * 2003-04-23 2007-09-11 Pfizer, Inc. Patent Department Cannabinoid receptor ligands and uses thereof
US7141669B2 (en) * 2003-04-23 2006-11-28 Pfizer Inc. Cannabiniod receptor ligands and uses thereof
US20040214856A1 (en) * 2003-04-23 2004-10-28 Pfizer Inc Cannabinoid receptor ligands and uses thereof
JP4041153B2 (ja) * 2003-05-07 2008-01-30 ファイザー・プロダクツ・インク カンナビノイド受容体リガンドとその使用
US20040224962A1 (en) * 2003-05-09 2004-11-11 Pfizer Inc Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss
WO2004113320A1 (en) * 2003-05-20 2004-12-29 The University Of Tennessee Research Foundation Cannabinoid derivatives, methods of making, and use thereof
US7232823B2 (en) * 2003-06-09 2007-06-19 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
US20040259887A1 (en) * 2003-06-18 2004-12-23 Pfizer Inc Cannabinoid receptor ligands and uses thereof
US20050026983A1 (en) * 2003-07-30 2005-02-03 Pfizer Inc Imidazole compounds and uses thereof
US7326706B2 (en) 2003-08-15 2008-02-05 Bristol-Myers Squibb Company Pyrazine modulators of cannabinoid receptors
US20050043327A1 (en) * 2003-08-21 2005-02-24 Pfizer Inc Pharmaceutical composition for the prevention and treatment of addiction in a mammal
US7151097B2 (en) * 2003-11-07 2006-12-19 Pfizer Inc. Bicyclic pyrazolyl and imidazolyl compounds and uses thereof
US20060025448A1 (en) 2004-07-22 2006-02-02 Cadila Healthcare Limited Hair growth stimulators
FR2882365B1 (fr) * 2005-02-21 2007-09-07 Sanofi Aventis Sa Derives de 2-(1,5-diphenyl-1h-pyrazol-3-yl)-1,3,4-oxadiazole leur preparation et leur application en therapeutique
EP1890767A2 (en) * 2005-05-27 2008-02-27 Pfizer Products Inc. Combination of a cannabinoid-1- receptor-antagonist and a microsomal triglyceride transfer protein inhibitor for treating obesity or mainataining weight loss
AU2006264649A1 (en) 2005-06-30 2007-01-11 Prosidion Limited GPCR agonists
TW200745096A (en) * 2005-08-23 2007-12-16 Organon Nv Indole derivatives
CN101096359B (zh) * 2006-06-29 2012-03-14 中国科学院上海药物研究所 一类多芳基取代甲烷氧或硅氧基胍类化合物及其制备方法和用途
EP2061767B1 (de) 2006-08-08 2014-12-17 Sanofi Arylaminoaryl-alkyl-substituierte Imidazolidin-2,4-dione, Verfahren zu ihrer Herstellung, diese Verbindungen enthaltende Arzneimittel und ihre Verwendung
EP2097410A4 (en) * 2006-09-29 2009-11-25 Green Cross Corp HETEROYL-PYRAZOLE DERIVATIVES AS CANNABINOID CB1 RECEPTOR ANTAGONISTS
KR20090064458A (ko) * 2006-10-20 2009-06-18 머크 앤드 캄파니 인코포레이티드 봄베신 수용체 아형-3 조절제로서의 치환된 이미다졸
EP2114933B1 (en) 2007-01-04 2011-09-07 Prosidion Ltd Piperidine gpcr agonists
EA016507B1 (ru) 2007-01-04 2012-05-30 Прозидион Лимитед Пиперидиновые агонисты gpcr
AR064735A1 (es) 2007-01-04 2009-04-22 Prosidion Ltd Agonistas de gpcr y composicion farmaceutica en base al compuesto
GB0700122D0 (en) 2007-01-04 2007-02-14 Prosidion Ltd GPCR agonists
PE20081849A1 (es) 2007-01-04 2009-01-26 Prosidion Ltd Derivados de piperidin-4-il-propoxi-benzamida como agonistas de gpcr
US20080207704A1 (en) * 2007-02-27 2008-08-28 The Green Cross Corporation Heteroaryl-imidazole derivatives as cannabinoid cb1 receptor antagonists
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
GB0720390D0 (en) 2007-10-18 2007-11-28 Prosidion Ltd G-Protein coupled receptor agonists
GB0720389D0 (en) 2007-10-18 2008-11-12 Prosidion Ltd G-Protein Coupled Receptor Agonists
DK2963031T3 (en) 2007-11-30 2019-04-23 Zynerba Pharmaceuticals Inc PROGRESS OF TETRAHYDROCANNABINOL, COMPOSITIONS COMPREHENSIVE PRODRUG OF TETRAHYDROCANNABINOL AND METHODS FOR USING THE SAME
WO2009078498A1 (en) * 2007-12-17 2009-06-25 Green Cross Corporation Biarylpyrazole 4-carboxamides as cannabinoid cb1 receptor ligands
AR072707A1 (es) 2008-07-09 2010-09-15 Sanofi Aventis Compuestos heterociclicos, procesos para su preparacion, medicamentos que comprenden estos compuestos y el uso de los mismos
DE102008057344A1 (de) 2008-11-14 2010-05-20 Bayer Schering Pharma Aktiengesellschaft Aminoalkyl-substituierte Aryl-Verbindungen und ihre Verwendung
DE102008057364A1 (de) 2008-11-14 2010-05-20 Bayer Schering Pharma Aktiengesellschaft Substituierte Aryl-Verbindungen und ihre Verwendung
DE102009041242A1 (de) 2009-09-11 2011-12-15 Bayer Schering Pharma Aktiengesellschaft Heterocyclisch substituierte Aryl-Verbindungen und ihre Verwendung
DE102009041241A1 (de) 2009-09-11 2011-08-04 Bayer Schering Pharma Aktiengesellschaft, 13353 Substituierte Aryl-Verbindungen und ihre Verwendung
DE102008057343A1 (de) 2008-11-14 2010-05-20 Bayer Schering Pharma Aktiengesellschaft Heterocyclisch substituierte Aryl-Verbindungen und ihre Verwendung
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
RU2012111354A (ru) 2009-08-26 2013-10-10 Санофи Новые кристаллические гидраты фторгликозидов, содержащие их фармацевтические препараты и их использование
KR20120092175A (ko) 2009-12-04 2012-08-20 죤 이. 그랜트 카테콜-0-메틸-트랜스퍼라제 저해제를 사용한 충동 제어 장애의 치료
WO2011157827A1 (de) 2010-06-18 2011-12-22 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
WO2012120050A1 (de) 2011-03-08 2012-09-13 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683703B1 (de) 2011-03-08 2015-05-27 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683698B1 (de) 2011-03-08 2017-10-04 Sanofi Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
US8828995B2 (en) 2011-03-08 2014-09-09 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2683700B1 (de) 2011-03-08 2015-02-18 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8710050B2 (en) 2011-03-08 2014-04-29 Sanofi Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8846666B2 (en) 2011-03-08 2014-09-30 Sanofi Oxathiazine derivatives which are substituted with benzyl or heteromethylene groups, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
US8901114B2 (en) 2011-03-08 2014-12-02 Sanofi Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
EP2683705B1 (de) 2011-03-08 2015-04-22 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2015162452A1 (en) * 2014-04-23 2015-10-29 Piramal Enterprises Limited Substituted pyrazole compounds as cb1 receptor antagonists and uses thereof
WO2016087615A1 (en) 2014-12-04 2016-06-09 Procomcure Biotech Gmbh Novel imidazole-based heterocyclic compounds
US10456379B2 (en) 2014-12-04 2019-10-29 Procomcure Biotech Gmbh Imidazole-based antimicrobial agents

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8613591D0 (en) * 1986-06-04 1986-07-09 Roussel Lab Ltd Chemical compounds
ES2037739T3 (es) * 1986-10-22 1993-07-01 Ciba-Geigy Ag Derivados del acido 1,5-difenilpirazol-3-carboxilico para la proteccion de plantas de cultivo.
PH27357A (en) * 1989-09-22 1993-06-21 Fujisawa Pharmaceutical Co Pyrazole derivatives and pharmaceutical compositions comprising the same
FR2665898B1 (fr) * 1990-08-20 1994-03-11 Sanofi Derives d'amido-3 pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
AU1191292A (en) * 1991-02-11 1992-09-07 Schering Agrochemicals Limited Imidazole pesticides
FR2692575B1 (fr) * 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
FR2707295A1 (fr) * 1993-06-07 1995-01-13 Rhone Poulenc Agrochimie Fongicides pyrazoles substitués en position 3 par un hétérocycle.
FR2714057B1 (fr) * 1993-12-17 1996-03-08 Sanofi Elf Nouveaux dérivés du 3-pyrazolecarboxamide, procédé pour leur préparation et compositions pharmaceutiques les contenant.
US5596106A (en) * 1994-07-15 1997-01-21 Eli Lilly And Company Cannabinoid receptor antagonists
FR2741621B1 (fr) * 1995-11-23 1998-02-13 Sanofi Sa Nouveaux derives de pyrazole, procede pour leur preparation et compositions pharmaceutiques en contenant
FR2742148B1 (fr) * 1995-12-08 1999-10-22 Sanofi Sa Nouveaux derives du pyrazole-3-carboxamide, procede pour leur preparation et compositions pharmaceutiques les contenant
DE69822449T2 (de) * 1997-01-21 2005-01-27 Smithkline Beecham Corp. Neue cannabinoidrezeptor-modulatoren
FR2758723B1 (fr) * 1997-01-28 1999-04-23 Sanofi Sa Utilisation des antagonistes des recepteurs aux cannabinoides centraux pour la preparation de medicaments
US6432947B1 (en) * 1997-02-19 2002-08-13 Berlex Laboratories, Inc. N-heterocyclic derivatives as NOS inhibitors
FR2761266B1 (fr) * 1997-03-28 1999-07-02 Sanofi Sa Composition pharmaceutique formee par granulation humide pour l'administration orale d'un derive du n-piperidino-3- pyrazolecarboxamide, de ses sels et de leurs solvates
AU751139B2 (en) * 1997-10-13 2002-08-08 Astellas Pharma Inc. Amide derivative
KR100652994B1 (ko) * 1998-09-11 2006-11-30 아방티 파르마 소시에테 아노님 아제티딘 유도체, 이의 제조방법 및 이를 함유하는 약제
FR2789079B3 (fr) * 1999-02-01 2001-03-02 Sanofi Synthelabo Derive d'acide pyrazolecarboxylique, sa preparation, les compositions pharmaceutiques en contenant
ES2234523T3 (es) * 1999-03-01 2005-07-01 Pfizer Products Inc. Acidos oxamicos que contienen ciano y sus derivados como ligandos de receptores tiroideos.
HUP0200248A3 (en) * 1999-03-01 2002-11-28 Pfizer Prod Inc Oxamic acids and derivatives as thyroid receptor ligands, pharmaceutical compositions containing them as active ingredient and their use
US6344481B1 (en) * 1999-03-01 2002-02-05 Pfizer Inc. Thyromimetic antiobesity agents
CN100400487C (zh) * 1999-04-30 2008-07-09 辉瑞产品公司 糖皮质激素受体调制剂
AU2935200A (en) * 1999-04-30 2000-11-17 Pfizer Products Inc. Compounds for the treatment of obesity
US20020169101A1 (en) * 1999-05-10 2002-11-14 Gonzalez Maria Isabel Treatment of sexual dysfunction
CA2325358C (en) * 1999-11-10 2005-08-02 Pfizer Products Inc. 7-¬(4'-trifluoromethyl-biphenyl-2-carbonyl)amino|-quinoline-3-carboxylic acid amides, and methods of inhibiting the secretion of apolipoprotein b
EP1125579A3 (en) * 2000-01-18 2003-01-02 Pfizer Products Inc. Uses of agrp-melanocortin receptor binding modulating compounds
EP1127882A1 (en) * 2000-01-25 2001-08-29 Pfizer Products Inc. Tetrazole compounds as thyroid receptor ligands
EP1254115A2 (en) * 2000-02-11 2002-11-06 Bristol-Myers Squibb Company Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators for treating respiratory and non-respiratory diseases
US6566356B2 (en) * 2000-03-03 2003-05-20 Aventis Pharma S.A. Pharmaceutical compositions containing 3-aminoazetidine derivatives, novel derivatives and their preparation
US6355631B1 (en) * 2000-03-03 2002-03-12 Aventis Pharma S.A. Pharmaceutical compositions containing azetidine derivatives, novel azetidine derivatives and their preparation
US6479479B2 (en) * 2000-03-03 2002-11-12 Aventis Pharma S.A. Azetidine derivatives, their preparation and pharmaceutical compositions containing them
EP1136071A3 (en) * 2000-03-22 2003-03-26 Pfizer Products Inc. Use of glycogen phosphorylase inhibitors
DZ3335A1 (fr) * 2000-03-23 2001-09-27 Solvay Pharm Bv Derives de 4,5-dihydro-1h-pyrazole ayant une activite antagoniste de cb1
GB0007405D0 (en) * 2000-03-27 2000-05-17 Smithkline Beecham Corp Compounds
US6664291B2 (en) * 2000-03-31 2003-12-16 Pfizer, Inc. Malonamic acids and derivatives thereof as thyroid receptor ligands
US6620830B2 (en) * 2000-04-21 2003-09-16 Pfizer, Inc. Thyroid receptor ligands
IL142707A0 (en) * 2000-04-27 2002-03-10 Pfizer Prod Inc Methods of treating obesity using a neurotensin receptor ligand
GB0011089D0 (en) * 2000-05-08 2000-06-28 Black James Foundation Gastrin and cholecystokinin receptor ligands (11)
US20020019421A1 (en) * 2000-07-05 2002-02-14 Roni Biberman Compositions and therapy for substance addiction
US20020028799A1 (en) * 2000-07-06 2002-03-07 Naylor Alasdair Mark Treatment of male sexual dysfunction
US20020052370A1 (en) * 2000-07-06 2002-05-02 Barber Christopher Gordon Cyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase
US20020165237A1 (en) * 2000-08-11 2002-11-07 Fryburg David Albert Treatment of the insulin resistance syndrome
IL145106A0 (en) * 2000-08-30 2002-06-30 Pfizer Prod Inc Intermittent administration of a geowth hormone secretagogue
AU2001294547A1 (en) * 2000-09-14 2002-03-26 Schering Corporation Substituted urea neuropeptide y y5 receptor antagonists
US20020091114A1 (en) * 2000-10-04 2002-07-11 Odile Piot-Grosjean Combination of a CB1 receptor antagonist and of sibutramine, the pharmaceutical compositions comprising them and their use in the treatment of obesity
AU2001292161A1 (en) * 2000-10-20 2002-04-29 Pfizer Products Inc. Alpha-aryl ethanolamines and their use as beta-3 adrenergic receptor agonists
JP2002193911A (ja) * 2000-10-28 2002-07-10 Pfizer Prod Inc グルココルチコイドレセプターモジュレーター
CA2429437A1 (en) * 2000-11-20 2002-05-23 Takeda Chemical Industries, Ltd. Imidazole derivatives, process for their preparation and their use
US20020091129A1 (en) * 2000-11-20 2002-07-11 Mitradev Boolell Treatment of premature ejaculation
US20030022891A1 (en) * 2000-12-01 2003-01-30 Anandan Palani MCH antagonists and their use in the treatment of obesity
ES2316486T3 (es) * 2000-12-21 2009-04-16 Schering Corporation Antagonsitas de los receptores y5 del neuropeptido y heteroaril-urea.
JP2004527476A (ja) * 2001-02-02 2004-09-09 ファイザー・インク 真性糖尿病の処置
JP2004520397A (ja) * 2001-02-15 2004-07-08 ファイザー・プロダクツ・インク 増殖性アクチベータ受容体（ｐｐａｒ）化合物
MXPA03007284A (es) * 2001-02-15 2003-12-04 Pfizer Prod Inc Agonistas de receptor activador del proliferador de peroxisomas.
EP1236723A1 (en) * 2001-03-01 2002-09-04 Pfizer Products Inc. Sulfamide derivatives useful as beta3 agonists and pharmaceutical uses thereof
US20020173502A1 (en) * 2001-03-09 2002-11-21 Allerton Charlotte Moira Norfor Pharmaceutically active compounds
US6831074B2 (en) * 2001-03-16 2004-12-14 Pfizer Inc Pharmaceutically active compounds
US6784185B2 (en) * 2001-03-16 2004-08-31 Pfizer Inc. Pharmaceutically active compounds
US6770645B2 (en) * 2001-03-16 2004-08-03 Pfizer Inc. Pharmaceutically active compounds
US6794387B2 (en) * 2001-03-28 2004-09-21 Pfizer Inc. Pharmaceutically active compounds
JP4280073B2 (ja) * 2001-04-12 2009-06-17 ファーマコペイア ドラッグ ディスカバリー， インコーポレイテッド Ｍｃｈアンタゴニストとして使用されるアリールピペリジンおよびビアリールピペリジン
JP2003069959A (ja) * 2001-06-14 2003-03-07 Sony Corp 映像信号処理回路、映像信号処理方法、および画像表示装置
EP1273582B1 (en) * 2001-07-05 2005-06-29 Pfizer Products Inc. Heterocyclo-alkylsulfonyl pyrazoles as anti-inflammatory/analgesic agents
WO2003007887A2 (en) * 2001-07-20 2003-01-30 Merck & Co., Inc. Substituted imidazoles as cannabinoid receptor modulators
US6509367B1 (en) * 2001-09-22 2003-01-21 Virginia Commonwealth University Pyrazole cannabinoid agonist and antagonists
DE60208132T2 (de) * 2001-09-26 2006-07-20 Pfizer Products Inc., Groton Indolcaroboxylsäure als Thyroidrezeptor-Liganden
US20030139386A1 (en) * 2001-12-21 2003-07-24 Sophie Cote Pharmaceutical compositions based on azetidine derivatives
US20040248956A1 (en) * 2002-01-29 2004-12-09 Hagmann William K Substituted imidazoles as cannabinoid receptor modulators
AU2003216579A1 (en) * 2002-04-12 2003-10-27 Pfizer Inc. Imidazole compounds as anti-inflammatory and analgesic agents
US6825209B2 (en) * 2002-04-15 2004-11-30 Research Triangle Institute Compounds having unique CB1 receptor binding selectivity and methods for their production and use

Also Published As

Publication number Publication date
CA2502511A1 (en) 2004-05-29
MXPA05004115A (es) 2005-06-22
EP1556373A1 (en) 2005-07-27
WO2004035566A1 (en) 2004-04-29
JP2006506366A (ja) 2006-02-23
AU2003267728A1 (en) 2004-05-04
US20040077650A1 (en) 2004-04-22

Similar Documents

Publication Publication Date Title
BR0314872A (pt) Ligandos do receptor canabinóide e usos dos mesmos
BRPI0410289A (pt) ligantes do receptor de canabinóides e suas utilizações
BR0210503A (pt) Ligandos para receptor de 5-ht e suas utilizações
BRPI0409689A (pt) ligantes do receptor de canabinóides e sua utilização
BRPI0409634A (pt) ligantes de receptores de canabinóides e utilização destes
BRPI0409791A (pt) ligandos de receptores de canabinóides e sua utilização
BRPI0407305A (pt) Ligantes do receptor de canabinóides e seus usos
BRPI0406957A (pt) Derivados de [1,3,5]triazina [1,5a] pirazol como ligandos do receptor canabinoìde
BRPI0411078A (pt) ligantes de receptores de canabinóides e seus usos
BRPI0411617A (pt) derivados de pirimidina como ligantes de receptores de canabinóides
BRPI0409701A (pt) ligantes de receptores de canabinóides e seus usos
EA200201247A1 (ru) Соединения для лечения болезни альцгеймера
BR0312729A (pt) Novos derivados de indol-3-enxofre
BR0309355A (pt) 2-(2,6-diclorofenil)-diarilimidazóis
BRPI0416299A (pt) compostos de pirazolila e imidazolila bacìclicos e suas utilizações
ATE343388T1 (de) Pde-v hemmer zur behandlung von morbus parkinson
DK1414494T3 (da) Hæmmende antistoffer af HER3-aktivitet
GB0318447D0 (en) Therapeutic agents
BR0316438A (pt) Uso de eritropoietina em doenças cardìacas
BR0307998A (pt) Hidroxietilaminas substituìdas
ATE389395T1 (de) Substituierte 2-aminotetraline zur vorbeugenden behandlung von morbus parkinson
BR0114059A (pt) Derivados de resorcinol
BRPI0413245A (pt) compostos heteroarila de 6 membros para o tratamento de distúrbio neurodegenerativos
HRP20050517B1 (hr) N-sulfonil-4-metilenamino-3-hidroksi-2-piridoni kao antimikrobni lijekovi
BR0209430A (pt) Compostos heterocìclicos

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]